Cargando…

ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways

The mortality rates of gastric cancer remain high due to limited therapeutic strategies. As a highly selective inhibitor of the BD2 domain of BET family proteins, ABBV-744 has potent chemotherapeutic activity against various human solid tumors. However, whether ABBV-744 has potential anti-tumor effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Kun, Tang, Jiatong, Fan, Shengxian, Su, Haochen, Yu, Ranran, Zhang, Yixuan, Wu, Hao, Lv, Ying, Zhang, Shu, Zou, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539879/ https://www.ncbi.nlm.nih.gov/pubmed/37769529 http://dx.doi.org/10.1016/j.neo.2023.100936

Ejemplares similares

The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas
por: Du, Juan, et al.
Publicado: (2016)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

PI3K/AKT/mTOR/p70S6K Pathway Is Involved in Aβ25-35-Induced Autophagy
por: Fan, Shengnuo, et al.
Publicado: (2015)

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
por: Shorning, Boris Y., et al.
Publicado: (2020)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Zearalenone Induces Apoptosis and Cytoprotective Autophagy in Chicken Granulosa Cells by PI3K-AKT-mTOR and MAPK Signaling Pathways
por: Zhu, Yifeng, et al.
Publicado: (2021)

Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma
por: Diniz, Paulo H. C., et al.
Publicado: (2020)

Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma
por: Yu, Xiying, et al.
Publicado: (2020)

Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers
por: Reddy, Dhanasekhar, et al.
Publicado: (2020)

Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway
por: Zhang, X., et al.
Publicado: (2019)

The PI3K-AKT-mTOR pathway activates recovery from general anesthesia
por: Zhang, Yun-Hui, et al.
Publicado: (2016)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
por: Fakhar, Zeynab, et al.
Publicado: (2021)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

Activation of the PI3K/Akt/mTOR/p70S6K Pathway is Involved in S100A4-induced Viability and Migration in Colorectal Cancer Cells
por: Wang, Haiyan, et al.
Publicado: (2014)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway
por: Ling, Li, et al.
Publicado: (2021)

Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
por: Stefani, Constantin, et al.
Publicado: (2021)

Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways
por: Subramonian, Divya, et al.
Publicado: (2020)

Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer
por: Heinonen, Henna, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_du9in8aetgk2aa5skdgsju71tg